@JStonker
Joined April 2020
  • Tweets994
  • Following87
  • Followers569
491Media
Not been able to find any official coverage or photos from ELRIG but sounds like the #AVCT presentation went down well
1
5
59
2,201
FAP targeting seems to be in vogue at EANM 2026 currently running in Vienna too linkedin.com/posts/jouke-boe…
1
14
283
#ESMO2026 abstracts published for #AVCT's AVA6000 and AVA6103 cslide.ctimeetingtech.com/es… cslide.ctimeetingtech.com/es…
1
3
54
3,158
Don't recall seeing STS specialist M M Gounder from MSKCC declaring funding from #AVCT before. Article published this week and all other disclosures I can find are recent. STS still in play? aacrjournals.org/clincancerr…
2
5
36
3,324
Some biopsies already taken. If you're this confident in your presentation when you've seen biopsies of AVA6103... #AVCT
1
1
65
2,238
'Much more coming in the next eight weeks.' ESMO update also sounding very signficant. Abstracts published this weekend. #AVCT
4
72
2,040
#AVCT presenting to investors at Jefferies Healthcare Conference next month
40
1,713
'The best preclinical to clinical translation I've seen in my career.' #AVCT
7
95
2,616
AVA6000 still sounding exciting - upcoming data and long term view of how patients are doing #AVCT
50
1,971
#AVCT at BioXconomy: Experience as a practicing oncologist brings 'different flavour' to CC's angle - 'if we do right by our patients we do right by our shareholders' Spend is quite low in earlier stage programs and increases as you move through drug discovery Thread 🧵
4
9
2
78
6,374
more replies
Concept of personalised/precision medicine comes into play here. Important to continue looking at this concept - what medicine will work best with what tumour? Important question for AVA6207, going after resistance mechanisms.
1
13
719
Please note I was paraphrasing a lot of this to fit the tweet character limit and also note down as much as I can - BioXconomy were recording the session so it may be published later on to hear exact wording of what was said 👍🏼
5
58
635
Load more